Investor Day: Aug. 11, 2022

Myriad Genetics hosted an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, research and development pipeline, and technology initiatives to expand its reach and make it easier for healthcare providers and their patients to benefit from genetic insights.

Events & Presentations

  • 08/04/2022

    Myriad Genetics Second Quarter 2022 Financial Earnings Call

  • 05/11/2022

    BofA Securities 2022 Healthcare Conference

  • 05/05/2022

    Myriad Genetics First Quarter 2022 Financial Results Conference Call

Latest News

Family Cancer History Still a Mystery to Many Women

September 28, 2022

Results from a nationwide survey conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovari...

Myriad Genetics Reports Second Quarter Financial Results

August 4, 2022

Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year an...

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

July 19, 2022

Myriad Genetics, Inc., (NASDAQ: MYGN), will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth ...

Stock Information

NASDAQ: MYGN

$19.58

0.5 (2.62)

10/03/2022

DAY HIGH

$19.87

YEAR HIGH

$33.09

DAY LOW

$18.91

YEAR LOW

$16.02

Financial Reports and Filings

  • 09/27/2022 4

    Statement of changes in beneficial ownership of securities
  • 09/27/2022 4

    Statement of changes in beneficial ownership of securities
  • 09/27/2022 4

    Statement of changes in beneficial ownership of securities

Our ESG Story

“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics. “I want to thank our 2,400 teammates for the progress we have made to date, recognizing we have more work to be done. We are committed to intensifying our ESG focus helping to address the needs of the patients, healthcare providers, stakeholders, and communities we serve.”

Screen Shot 2022-08-01 at 2.32.33 PM